20

25

30

400

What is claimed is:

- 1. An isolated ^{Ps}p45 protein comprising at least one of the following:
- (a) the amino acid sequence of SEQ ID NO: 4 comprising a conservative amino acid substitution; and
- (b) an amino acid sequence that has at least 70% identity with the amino acid sequence of SEQ ID NOs: 2 or 4.
- 2. An isolated antigenic fragment of the ^{Ps}p45 protein of Claim 1.
 - 3. A recombinant polypeptide comprising the amino acid sequence of the Ps p45 protein of Claim 1 or the antigenic fragment of Claim 2.
- 15 4. The recombinant polypeptide of Claim 3 that is a chimeric protein.
 - 5. An antibody raised against at least one of the following:
 - (a) the isolated ^{Ps}p45 protein of Claim 1;
 - (b) the isolated antigenic fragment of Claim 2;
 - (c) the recombinant polypeptide of Claim 3; and
 - (d) the recombinant polypeptide of Claim 4.
 - 6. An isolated or recombinant nucleic acid encoding at least one of the following:
 - (a) the isolated Psp45 protein of Claim 1;
 - (b) the isolated antigenic fragment of Claim 2;
 - (c) the recombinant polypeptide of Claim 3; and
 - (d) the recombinant polypeptide of Claim 4.
 - 7. The nucleic acid of Claim 6 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3.



- 8. A nucleic acid that hybridizes to the nucleotide sequence of Claim 7; wherein said nucleic acid comprises at least 12 nucleotides.
- 9. An expression vector, comprising the nucleic acid of any of Claims 6-8, and a transcriptional control sequence, wherein the nucleic acid is operatively linked to the transcriptional control sequence.
 - 10. A host cell that comprises the expression vector of Claim 9.
- 11. A method for producing a recombinant polypeptide comprising culturing the host cell of Claim 10 in a culture medium, wherein the host cell expresses the nucleic acid encoding the recombinant polypeptide; and whereby the recombinant polypeptide is produced.
- 15 12. The method of Claim 11 wherein the host cell is an E. coli cell.
 - 13. A method of obtaining a purified recombinant polypeptide comprising purifying the recombinant polypeptide produced by the method of Claim 12 from the culture medium.
 - 14. The purified recombinant polypeptide obtained by the method of Claim 13.
- 15. A recombinant *Yersinia ruckeri* cell comprising the nucleic acid of any of Claims 6-8.
 - 16. The recombinant *Yersinia ruckeri* cell of Claim 15 that has the BCCM accession No. of LMG P-22044.
- 17. A Yersinia ruckeri cell having the BCCM accession No. LMG P-22511.

20

30

 (\cdot)

- 18. A vaccine that comprises at least one of the following:
 - (a) the isolated ^{Ps}p45 protein of Claim 1;
 - (b) the isolated antigenic fragment of Claim 2;
 - (c) the recombinant polypeptide of Claim 3; and
- (d) the recombinant polypeptide of Claim 4.
 - 19. A vaccine that comprises the nucleic acid of any of Claims 6-8.
- 20. A vaccine comprising the recombinant *Yersinia ruckeri* cell of Claim 15 or 16.
 - 21. The vaccine of Claim 20, wherein said recombinant *Yersinia ruckeri* cell is a bacterin.
- 15 22. A vaccine comprising the recombinant *Yersinia ruckeri* cell of Claim 17.
 - 23. The vaccine of Claim 22, wherein said recombinant *Yersinia ruckeri* cell is a bacterin.
 - 24. The vaccine of Claim 23, further comprising a second *Yersinia* ruckeri cell having the BCCM accession No. LMG P-22044, wherein said second *Yersinia* ruckeri cell is a bacterin.
- 25 25. The vaccine of any of Claims 18-24 further comprising an antigen obtained from an Infectious Pancreatic Necrosis (IPN) virus.
 - 26. The vaccine of Claim 25 wherein the antigen obtained from the IPN virus is selected from the group consisting of the VP2 var protein and the VP3 protein.
 - 27. The vaccine of any of Claims 18-24 further comprising both the VP2 var protein and the VP3 protein from Infectious Pancreatic Necrosis (IPN) virus.

10

20

- 28. The vaccine of Claim 27 wherein the VP2 var protein is obtained from a transformed *Pichia pastoris* cell, BCCM Accession No. IHEM 20069 and the VP3 protein is obtained from a transformed *Pichia pastoris* cell, BCCM Accession No. IHEM 20071.
- 29. The vaccine of Claim 27 wherein the VP2 var protein is obtained from a transformed *Pichia pastoris* cell, BCCM Accession No. IHEM 20070 and the VP3 protein is obtained from a transformed *Pichia pastoris* cell, BCCM Accession No. IHEM 20072.
- 30. The vaccine of any of Claims 18-29 that further comprises an antigen obtained from *Aeromonas salmonicida*.
- 15 31. A method of protecting a fish from salmonid rickettsial septicemia comprising administering to the fish the vaccine of any of Claims 18-30.
 - 32. The method of Claim 31 wherein the fish is a teleost.
 - 33. The method of Claim 32 wherein the teleost is a salmonid.
- 34. A method of protecting a fish from salmonid rickettsial
 septicemia and Infectious Pancreatic Necrosis comprising administering to
 the fish the vaccine of any of Claims 25-30.
 - 35. The method of Claim 34 wherein the fish is a salmonid.
- 36. The method of Claim 33 or 35 wherein the salmonid is selected from the group consisting of a *Salmo salar* (Atlantic salmon), an *Oncorhynchus kisutch* (coho salmon) and an *Oncorhynchus mykiss* (rainbow trout).

37. A vaccine to protect against an intracellular pathogen for use in a non-human animal comprising a recombinant enteric bacterium that encodes a surface antigen of the intracellular pathogen.

5 38. The vaccine of Claim 37 wherein the recombinant enteric bacterium is inactivated.

10

15

20

- 39. The vaccine of Claim 38 wherein the non-human animal is a fish.
- 40. The vaccine of Claim 39 wherein the surface antigen is an outer membrane protein.
- 41. The vaccine of Claim 40 wherein the recombinant enteric bacterium is Yersinia ruckeri.
 - 42. A method of vaccinating a non-human animal comprising administering to the non-human animal the vaccine of any of Claims 37-41.